logo logo


The expanding universe of IP
Granting data exclusivity for clinical trials would undermine access to medicines.
CETA bringing changes to pharma patents in Canada
A certificate of supplemental protection provides up to two years of additional protection after expiry of a patent.
Compulsory licensing in Colombia: Leaked documents show aggressive lobbying by Novartis
Confidential documents obtained by Public Eye show that Novartis has threatened Colombia with international investment arbitration under its BIT with Switzerland to avoid the issuance of a compulsory license
Gilead Pharma corp withdraws investment arbitration after Ukraine agrees to settlement of dispute over monopoly rights to market anti-viral drug
Ukraine has settled a dispute with American pharmaceutical company Gilead Sciences Inc., following the company’s pursuit of legal remedies in both domestic courts and via investment arbitration.
Proposed trade pact clause on intellectual property could endanger India’s TB programme
A draft of the Regional Comprehensive Economic Partnership agreement reveals three clauses that could potentially hurt production of important generic drugs
What to watch out for in the EU-Mercosur FTA negotiations: consequences for access to medicines
Some of the main TRIPS-plus measures historically pushed for by countries such as the United States or the EU are being again proposed at the EU-Mercosur FTA.
Switzerland wants stricter intellectual property rules in India that could harm generic drug makers
Switzerland is pushing for tighter patent protection, data exclusivity and dropping compulsory licencing under a new free trade agreement.
Leaked document: Note by Switzerland on India EFTA TEPA IP Chapter
In this note, Switzerland is proposing that India agree to broader patentable subject matter, particularly as regards biologic products.
India–EFTA trade talks may make medicines more expensive
MSF and civil society urge Swiss negotiators not to undermine the ‘pharmacy of the developing world’
Stop RCEP. Trade for the People. Not for Corporate Elites
People Over Profit Statement on the 17th Round of Negotiations of the Regional Comprehensive Economic Partnership (RCEP) in Kobe, Japan 27 Feb-3 March 2017
RCEP investment chapter presents a grave threat to access to medicines
Médecins Sans Frontières (MSF) raises concerns over provisions under negotiation in the RCEP investment chapter that threaten to restrict access to affordable medicines for millions of people
16-nation RCEP talks resume in wake of TPP’s demise
The RCEP Kobe conference is the first round of negotiations this year and the first since U.S. President Donald Trump announced he was canceling America’s participation in the Trans-Pacific Partnership. The Kobe meeting will set the tone for the remaining negotiations this year, however NGO representatives, noted that the TPP would be the elephant in the room.
RCEP and health: this kind of ‘progress’ is not what India and the world need
Concerns remain over the impact of RCEP negotiations on public health and access to medicines.
India should not let Europe undermine its new BIT and TRIPs flexibilities for medicines
There is no principled basis for EU’s demand of extending patent protection beyond the period of 20 years.
MSF calls on Japan and South Korea to drop the harmful RCEP measures
The intellectual property provisions initiated by Japan and South Korea go far beyond the requirements needed under international trade rules.
TPP is dead, but its legacy lives on
The Trans-Pacific Partnership was dead long before Donald Trump signed his executive order. But its damaging aspects, like stringent IP provisions, have just migrated to other agreements
Implementation of Indo-Japan free trade agreement needs to be expedited: Nirmala Sitharaman
The pace of implementation of Indo-Japan free trade agreement needs to be further enhanced in order to exploit the huge potential of the pact, Commerce and Industry Minister Nirmala Sitharaman said.
Report shows trade agreements have boosted medicine and copyright monopolies
Global pharmaceutical companies have successfully lobbied for longer monopolies in trade agreements which have delayed the availability of cheaper medicines, resulting in higher prices.
Longer monopolies and single legal proceedings vs. generics - the gift of CETA to Canadian drug patentees
Canadian pharmaceutical patent owners can expect two substantive changes in the next year following implementation of the Canada–European Union trade agreement